TR-M225832 - metapramine-d3 | 1794942-17-8

Metapramine

<p>Applications Metapramine is a tricyclic antidepressant derived from dibenzoazepine. Metapramine acts as a norepinephrine reuptake inhibitor without affecting the reuptake of serotonin or dopamine.<br>References Dagonneau, H. et al.: Comp. Rend. Sea. Soc. Biol. Ses Fil., 180, 53 (1986); Bonierbale M. et al.: L'Encéphale, 2, 219 (1976); Cuenca, E. et al.: Arch. Farmacol. Toxicol., 5, 154 (1979);<br></p>

<p>Metapramine, a tricyclic antidepressant, blocks norepinephrine reuptake and is a low-affinity NMDA antagonist.</p>

<p>Applications 10,11-Dihydro-5-methyl-5H-dibenz[b,f]azepin-10-ol is a metabolites of Metapramine (M225830), found in plasma in depressed inpatients.<br>References Bougerol, T., et al.: Encephale., 16, 35 (1990); Das, B. P., et al.: J, Med. Chem., 13, 979 (1970);<br></p>

Metapramine is a drug that belongs to the group of tricyclic antidepressant drugs. It is used in the treatment of chronic oral infections, such as periodontitis and dental caries, as well as infectious diseases. Metapramine has been shown to inhibit the activity of toll-like receptor 2 (TLR2) and TLR4, which are receptors that recognize bacterial and viral components. The pharmacological effects of metapramine are mediated by its ability to bind to adenosine A3 receptors. This binding inhibits the release of proinflammatory cytokines and chemokines from immune cells that have been stimulated by Toll-like receptor ligands. Metapramine is also known for its cardiac effects, including prolongation of QT interval on ECG recordings.